About CSID
Congenital Sucrase-Isomaltase Deficiency (CSID) also known as Genetic Sucrase-Isomaltase Deficiency (GSID).
How to Diagnose CSID
The clinical diagnosis of CSID can be challenging. Here are available objective tests that can aid in your diagnosis.
About Sucraid®
Sucraid® is the only FDA-approved enzyme replacement therapy indicated for the treatment of CSID.
How to Order
Information on ordering Sucraid® and programs to make Sucraid® affordable for all patients.
What is Sucraid®?
Sucraid® is an enzyme replacement therapy that contains sacrosidase as a substitute for sucrase, which is one of the enzymes that is defective in individuals who have Congenital Sucrase-Isomaltase Deficiency (CSID).
Sacrosidase facilitates the breakdown of sucrose (sugar) into its constituent monosaccharide units, glucose and fructose, for absorption from the small intestine. Sucraid® has been documented to help relieve the gastrointestinal symptoms associated with CSID, and as a result, help affected individuals consume a more normal diet that includes sucrose-containing foods.
Proper dosing is essential for Sucraid® to be effective.
The proper Sucraid® dose depends on the patient’s body weight. The dose for patients weighing 33 lb or less is 1 mL, and is 2 mL for patients weighing more than 33 lb. Sucraid® is available in 118 mL (4 fluid oz) bottles or 2 mL single-use containers. Each single-use container holds one dose for patients over 33 lb and up to 2 doses for patients weighing 33 lb and less.
The appropriate dose of Sucraid® is to be taken orally with each meal or snack, diluted with 4 ounces (120 mL) of water, milk, or infant formula. Please refer to the Prescribing Information and Instructions for Use for full dosing instructions. Because heat or acidity may decrease the potency of Sucraid®, the diluting liquid should not be a warmed or acidic liquid such as fruit juice. It is recommended that approximately half the dose be taken at the beginning of a meal or snack, and the remainder taken during a meal or snack.